Carb-X company information, Employees & Contact Information

Catalyzing Change: Entrepreneurs from the Global South Leading the Fight against Antimicrobial Resistance ACS Publications

Antibiotics re-booted—time to kick back against drug resistance Nature

Kinvard Bio Secures Follow-on CARB-X Funding to Accelerate Development of Next-Generation Antibiotics PR Newswire

CARB-X and CHAI partner to sharpen AMR response, tackle gonorrhea in low- and middle-income countries Clinton Health Access Initiative

Clarametyx Biosciences Awarded a Multi-Phased Agreement With CARB-X to Accelerate Anti-Biofilm Vaccine to Prevent Bacterial Infections Business Wire

CARB-X Grants Debiopharm an Additional $12.3 Million to Advance Development of Novel Antibiotic Against Gonorrhea FinancialContent

Self-Adaptive Quantum Kernel Principal Component Analysis for Compact Readout of Chemiresistive Sensor Arrays Wiley

Novo Nordisk Foundation partners with CARB-X to fight drug-resistant infections Novo Nordisk Fonden

Changing Priorities in Vaccinology: Antibiotic Resistance Moving to the Top Frontiers

Expanding antibiotic, vaccine, and diagnostics development and access to tackle antimicrobial resistance The Lancet

CARB-X funds the Myers Research Group to develop enhanced oral… Harvard Office of Technology Development

[Event Report] The 49th Special Breakfast Meeting – Push and Pull Incentives to Address AMR: The Experience of CARB-X and the potential for Public-Private Partnerships in Global Health (September 21, 2022) 日本医療政策機構

CARB-X Announces First Award Of 2018; Seeks Partners For Antibacterial Research Intellectual Property Watch

Breathing easy thanks to new antibiotics Helmholtz-Zentrum für Infektionsforschung

The silent pandemic: Emergent antibiotic resistances following the global response to SARS-CoV-2 ScienceDirect.com

The CARB-X Portfolio of Nontraditional Antibacterial Products ACS Publications

Antibiotics in the clinical pipeline as of December 2022 - The Journal of Antibiotics Nature

CARB-X Awards Additional Funding to Debiopharm for Continued Development of Early-Stage Antibiotic Targeting Drug-Resistant N. Gonorrhoeae Infections FinancialContent

A Review of Antibacterial Candidates with New Modes of Action ACS Publications

Incentivising innovation in antibiotic drug discovery and development: progress, challenges and next steps Nature

2024 News University of Maryland School of Medicine

Novel insights from financial analysis of the failure to commercialise plazomicin: Implications for the antibiotic investment ecosystem | Humanities and Social Sciences Communications Nature

SNIPR Biome receives funding from CARB-X to support GlobeNewswire

Antibiotic Alternatives Special Issue ACS Publications

Small-Molecule Antibiotic Drug Development: Need and Challenges ACS Publications

The Superbug Fight Needs a Better Business Model Global Health NOW

Implementing an EU pull incentive for antimicrobial innovation and access: blueprint for action The Lancet

Intravacc Awarded US$ 633K CARB-X Funding to Develop a Vaccine that Prevents Gonorrhea Infections Yahoo Finance

Boston University Names 11th President: Melissa L. Gilliam, Physician, Educator, Scholar | BU Today Boston University

Kevin Outterson, CARB-X executive director (IMAGE) EurekAlert!

Superbug killer: New synthetic molecule highly effective against drug-resistant bacteria EurekAlert!

Designing development programs for non-traditional antibacterial agents Nature

Antimicrobial multidrug resistance in the era of COVID-19: a forgotten plight? BioMed Central

The first infection diagnostic emerges from Carb-X Chemical & Engineering News

Funding for the development of an inhibitor against hospital germs Helmholtz-Zentrum für Infektionsforschung

Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis The Lancet

Latest Update on Antimicrobial Resistant Gonorrhea: Challenges and Control Measures Infection Control Today

Infectious Disease Threats in the Twenty-First Century: Strengthening the Global Response Frontiers

Identification of potential vaccines for use with microarray patches in low- and middle-income countries: An assessment from the Vaccine Innovation Prioritisation Strategy Alliance ScienceDirect.com

A low-carb diet increases fecal short-chain fatty acids in feces of obese women following a weight-loss program: randomized feeding trial | Scientific Reports Nature

Effects of low-carbohydrate diets, with and without caloric restriction, on inflammatory markers in adults: a systematic review and meta-analysis of randomized clinical trials | European Journal of Clinical Nutrition Nature

The effects of low-carbohydrate diet on glucose and lipid metabolism in overweight or obese patients with T2DM: a meta-analysis of randomized controlled trials Frontiers

Oxford Drug Design receives over £8m in grant and equity investment UK Tech Investment News

Wising up: How generative AI could change the way we think CSIRO

Kick-start the future: Looking forward to 2050 CSIRO

Dietary carbohydrate intake and mortality: a prospective cohort study and meta-analysis The Lancet

Aussies provide more than 62 million species records for conservation research CSIRO

CSIRO scientists sequence first ever Spotted Handfish genome CSIRO

Telehealth and technology during COVID-19 CSIRO

Aussie innovators recognised at CSIRO’s ON Accelerate 8 Showcase CSIRO

Regional University Industry Collaboration Program CSIRO

New $18M partnership building digital tech for safer workplaces CSIRO

Indigenous ecological knowledge kept alive through new language exchange CSIRO

Sweet opportunity for Australian exotic mushroom growers CSIRO